bafetinib

A Bcr-Abl/Lyn dual tyrosine kinase inhibitor, which may suppress the growth of CLL cells by inhibition of Lyn kinase. Imatinib-resistant CLL cells are associated with an overexpression of Lyn kinase, a factor in the proliferation and survival of B-CLL cells. It has no effect on c-Src kinase activity, and may be less toxic than other broad Src family kinase inhibitors. Bafetinib has shown therapeutic potential in phase-II trials in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia.

References in periodicals archive ?

They show that giving the leukemia drugs nilotinib or bafetinib to fly larvae with the equivalent of Fragile X prevented the wild overgrowth of neuron endings associated with the disorder.

Cancer Drugs for Treating Brain Disorders?

Its oncology pipeline includes three programmes in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib.

CytRx gets NASDAQ confirmation of compliance

Net proceeds from the proposed offering will be used by the company to fund the clinical development of its drug candidates INNO-206, bafetinib and tamibarotene, for general corporate purposes, as working capital, capital expenditures, research and development expenditures and other commercial expenditures.

CytRx Corporation intends public offering of shares and warrants

That includes two trials for bafetinib, a possible treatment for people with certain advanced forms of leukemia.

Biotechnology company CytRx Corp (Los Angeles CA) said its loss narrowed in 2009 as revenue increased and research and development costs fell

15 January 2010 - US-based biopharmaceutical company CytRx Corporation (NASDAQ:CYTR) said on Wednesday it plans to initiate a Phase II proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib (formerly known as INNO-406) in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

Bafetinib is a potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, which is currently being planned as a third-line treatment for patients with chronic myeloid leukemia (CML) or certain forms of acute myeloid leukemia (AML) that are refractory or intolerant of other approved treatments.

In the planned Phase II trial, approximately 20 patients who have failed treatment with first-line agents will be administered daily oral doses of bafetinib. Patients will be monitored for clinical response, time to disease progression and cancer progression-free survival.